Apr 25, 2023 / 05:00PM GMT
Operator
Good afternoon, and welcome to Ionis' conference call to review the Phase III data for eplontersen. As a reminder, this call is being recorded. At this time, I would like to turn the call over to Wade Walke, Senior Vice President of Investor Relations, to lead off the call. Please begin.
D. Wade Walke - Ionis Pharmaceuticals, Inc. - SVP of IR
Thank you, Jason. Hello, and thank you for joining us as we discuss the results from our Phase III NEURO-TTRansform study of eplontersen in patients with hereditary ATTR polyneuropathy, which were presented yesterday at the American Academy of Neurology Annual Meeting. Before we begin, I encourage everyone to go to the Investors section of the Ionis website to view the press release we issued yesterday as well as the AAN presentation and poster and the slides we will be using on today's webcast.
I would first like to draw your attention to Slide 2, which contains our forward-looking statements. Our discussion today will contain forward-looking statements based on our current expectations and beliefs. Such
Ionis Pharmaceuticals Inc To Discuss Eplontersen NEURO-TTRansform 66-Week Results Call Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers